検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1635 : K-562  update : 2024/05/30
細胞特性(Comment:英)Human cell line derived from chronic myelogenous leukemia. Can produce hemoglobin in the presence of NaB. Directly deposited from the institution that has established this cell line.
細胞特性(日)
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)ヒト慢性骨髄性白血病由来細胞株。NaBの添加によりヘモグロビンを産生する。本細胞株を樹立した機関から直接入手した株。
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Ichiki, T. Albert
樹立者 Lozzio, C.B. & Lozzio, B.B.
寄託日 2000
動物種 _human < Mammals
属名 Homo
種名 sapiens
性別 Female
53 years
採取組織 pleural effusion
病名 chrinic myelogenous leukemia
細胞分類 cancer
入手歴 overseas
細胞寿命 infinite
細胞形態 lymphoblast-like
Cellosaurus(Expasy) CVCL_0004
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Suspension cells
培地 MEM + 15% FBS + 0.1mM NEAA
培養方法 浮遊細胞の培養に関する一般的な注意
抗生物質 Free
継代方法 dilution
播種細胞数 1.5 x 10 4 cells/ml
継代密度 1 : 10 split
継代・培地交換頻度 Subculture : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 5% Glycerol
凍結方法 Slow freezing
マイコプラズマ (-)
ウィルス(HIV) LT 400
ウィルス(HTLV-1) (-)
アイソザイム検査 LD, NP
染色体検査 62-67(50) : /63(3),64(8),65(33),66(4),67(1)
個体識別検査 OK
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 31件
Reference(日) 1件
利用者成果(英) 4件
利用者成果(日) 0件

トップへページトップへ
Reference(英)
117  Baker EJ, Ichiki AT, Day NE, Andrews RB, Bamberger EG, Lozzio CB.  Simultaneous flow cytometric measurement of K-562 megakaryocytic differentiation and CD56+ large granular lymphocyte cytotoxicity  J Immunol Methods  2001  253(1-2):37-44  PubMed ID: 11384667  
98  Baker EJ, Ichiki AT, Hodge JW, Sugantharaj D, Bamberger EG, Lozzio CB.  PMA-treated K-562 leukemia cells mediate a TH2-specific expansion of CD4+ T cells in vitro  Leuk Res  2000  24(12):1049-57.  PubMed ID: 11077119   DOI: 10.1016/s0145-2126(00)00082-5
97  Ichiki AT, Langenberg M, Baker EJ, Hodge JW, Bamberger EG, Gerard DA, Lozzio CB.  Differential regulation of interleukin-1alpha and interleukin-1beta in K-562 cells  J Interferon Cytokine Res  1998  18(12):1045-50  PubMed ID: 9877448   DOI: 10.1089/jir.1998.18.1045
101  Wust CJ, Hodge JW, Ichiki AT, Lozzio CB.  Cell death in the human leukemia cell line, K-562, induced by antiserum and monoclonal antibodies  Leuk Res  1991  15(6):497-506  PubMed ID: 1713636   DOI: 10.1016/0145-2126(91)90061-w
103  Ichiki AT, Sugantharaj DG, Hudson CS, Gerard DA, Barnhill MA, Bamberger EG, Wust CJ, Fuhr JE, Lozzio CB.  Lowered susceptibility of K-562 cells treated with gamma interferon in serum-free medium to natural killer cell-mediated cytolysis  Nat Immun Cell Growth Regul  1988  7(5-6):297-304  PubMed ID: 3146698  
106  Walter H, Krob EJ, Al-Romaihi FA, Johnson D, Lozzio CB.  Detection of surface differences between closely related cell populations by partitioning. Cultured K-562 cell sublines  Cell Biophys  1988  13(3):173-87  PubMed ID: 2465826   DOI: 10.1007/BF02918374
5042  Haruta Y, Seon BK.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.  Proc Natl Acad Sci U S A  1986  83(20):7898-902  PubMed ID: 3464004   DOI: 10.1073/pnas.83.20.7898
95  Ichiki AT, Bamberger EG, Wust CJ, Lozzio CB.  Diversity of cell surface hematopoietic antigens on K-562 sublines identified with monoclonal antibodies  Leuk Res  1986  10(5):565-74  PubMed ID: 2940421   DOI: 10.1016/0145-2126(86)90092-5
96  Ichiki AT, Wust CJ, Lozzio CB.  Characterization of the Fc(IgG) receptor on the pluripotential leukaemia cell K-562  Clin Exp Immunol  1985  59(1):64-8  PubMed ID: 3971599  
116  Rowley PT, Ohlsson-Wilhelm BM, Wisniewski L, Lozzio CB, Lozzio BB.  K562 human leukemia cell passages differ in embryonic globin gene expression  Leuk Res  1984  8(1):45-54  PubMed ID: 6199625  
100  Lozzio BB, Machado EA, Mitchell J, Lozzio CB, Wust CJ, Golde DW.  Proliferation of human malignant hematopoietic cells in immunodeficient mice: suppression by antibody to pluripotent K-562 leukemia cells involves direct cytolysis and effector cells  Blood  1983  61(6):1045-53  PubMed ID: 6132631  
94  Wust CJ, Green M, Lozzio CB, Lozzio BB.  Antibody-dependent cytolysis of the human leukemia cell line K-562 in the absence of effector cells or complement  Blood  1982  59(1):133-40  PubMed ID: 7053760  
102  Ichiki AT, Lozzio BB, Wust CJ, Lozzio CB.  Relationship between the Fc receptor for IgG and the specific associated antigen of the pluripotential leukaemia cell line, K-562  Clin Exp Immunol  1982  50(2):360-5  PubMed ID: 6185259  
105  Machado EA, Gerard DA, Mitchell JR, Lozzio BB, Lozzio CB.  Arrest and extravasation of neoplastic cells. An electron microscopy study of serial sections at sequential stages  Virchows Arch A Pathol Anat Histol  1982  396(1):73-89  PubMed ID: 7123846   DOI: 10.1007/BF00428501
107  Lozzio CB, Lozzio BB, Wust CJ, Bamberger EG, Golde DW, Minowada J.  Antibody lysis of human hematopoietic cells in the absence of complement and effector cells  Exp Hematol  1982  10(8):698-707  PubMed ID: 6183138  
115  Perez RL, Mitchell JR, Lozzio BB.  Relevance of lipids to heterotransplantation of human malignancies  Oncology  1982  39(3):179-84  PubMed ID: 7043353   DOI: 10.1159/000225632
87  Lozzio BB, Lozzio CB, Bamberger EG, Feliu AS.  A multipotential leukemia cell line (K-562) of human origin  Proc Soc Exp Biol Med  1981  166(4):546-50  PubMed ID: 7194480   DOI: 10.3181/00379727-166-41106
93  Fuhr JE, Bamberger EG, Lozzio CB, Lozzio BB.  Induction of hemoglobin synthesis in original K 562 cell line  Blood Cells  1981  7(2):389-99  PubMed ID: 6170369  
108  Latif ZA, Lozzio BB, Wust CJ, Krauss S, Aggio MC, Lozzio CB.  Evaluation of drug-antibody conjugates in the treatment of human myelosarcomas transplanted in nude mice  Cancer  1980  45(6):1326-33  PubMed ID: 6928397   DOI: 10.1002/1097-0142(19800315)45:6<1326::aid-cncr2820450610>3.0.co;2-y
113  Lair SV, Lozzio BB.  Thymocyte reconstitution of athymic and athymic-asplenic mice: graft rejection and antibody synthesis  Exp Cell Biol  1980  48(6):439-44  PubMed ID: 6967835   DOI: 10.1159/000163010
969  Rutherford TR, Clegg JB, Weatherall DJ.  K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin.  Nature  1979  280(5718):164-5  PubMed ID: 95354   DOI: 10.1038/280164a0
970  Andersson LC, Jokinen M, Gahmberg CG.  Induction of erythroid differentiation in the human leukaemia cell line K562.  Nature  1979  278(5702):364-5  PubMed ID: 570644   DOI: 10.1038/278364a0
89  Lozzio BB, Machado EA, Lair SV, Lozzio CB.  Reproducible metastatic growth of K-562 human myelogenous leukemia cells in nude mice  J Natl Cancer Inst  1979  63(2):295-9  PubMed ID: 287825  
112  Lozzio CB, Lozzio BB, Wust CJ, Kim J.  Correlation of leukemia-associated antigens and Ph1 chromosome in fibroblastlike cells derived from bone marrow  Blood  1978  52(4):673-80  PubMed ID: 99197  
114  Lozzio BB, Lozzio CB, Bamberger EG.  Cytotoxicity of a factor from normal and abnormal human spleens for allogenic leukemia cells  Am J Hematol  1978  4(1):57-65  PubMed ID: 655158   DOI: 10.1002/ajh.2830040108
99  Collins JL, Wust CJ, Lozzio BB, Lozzio CB.  Characterization of an antigen from the myelogenous leukemia cell line K-562  J Natl Cancer Inst  1977  59(6):1667-74  PubMed ID: 72824   DOI: 10.1093/jnci/59.6.1667
109  Lozzio BB, Lozzio CB, Krauss S, Wust CJ, Girardi A.  Leukemia-associated antigens detected by a nonhuman primate antiserum to a Ph1+ myeologenous leukemia cell line  Blood  1977  50(1):115-24  PubMed ID: 68791  
111  Lozzio BB, Machado EA, Lair SA, Lozzio CB.  Suppression of human myelosarcoma growth in athymic mice by a primate antiserum  Cancer Treat Rep  1977  61(9):1679-84  PubMed ID: 271518  
88  Lozzio CB, Lozzio BB, Yang WK, Ichiki AT, Bamberger EG.  Absence of thymus-derived lymphocyte markers in myelogenous leukemia (Ph1+) cell line K-562  Cancer Res  1976  36(12):4657-62  PubMed ID: 63324  
104  Lozzio BB, Lozzi CB, Machado E.  Human myelogenous (Ph+) leukemia cell line: transplantation into athymic mice  J Natl Cancer Inst  1976  56(3):627-9  PubMed ID: 1062625   DOI: 10.1093/jnci/56.3.627
110  Lozzio BB, Machado EA, Lozzio CB, Lair S.  Hereditary asplenic-athymic mice: transplantation of human myelogenous leukemic cells  J Exp Med  1976  143(1):225-31  PubMed ID: 53268   DOI: 10.1084/jem.143.1.225

トップへページトップへ
Reference(日)
1222  角純子  バイオテクノロジ-素材としての培養細胞 細胞分化(I)  蛋白質 核酸 酵素  1988  33   

トップへページトップへ
利用者成果(英)
21717  Kasai F, Mizukoshi K, Nakamura Y.  Variable characteristics overlooked in human K-562 leukemia cell lines with a common signature  Sci Rep  2024  14(1):9619  PubMed ID: 38671192   DOI: 10.1038/s41598-024-60271-8
12492  Aoyama T, Shibayama Y, Furukawa T, Sugawara M, Takekuma Y.  Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells  Biol Pharm Bull  2019  42(11):1805-1813  PubMed ID: 31434819   DOI: 10.1248/bpb.b19-00185
13861  Tazawa Y, Usukubo I, Takada K, Takekuma Y, Shibayama Y, Sugawara M.  Schedule-dependent cytotoxicity of Etoposide and cyclophosphamide in P-glycoprotein-expressing human leukemic K-562 cells  Biol Pharm Bull  2014  37(8):1323-9  PubMed ID: 25087953   DOI: 10.1248/bpb.b14-00207
13862  Tazawa Y, Matsumura K, Takekuma Y, Sugawara M.  Schedule-dependent cytotoxicity of etoposide (VP-16) and cyclophosphamide in leukemia cell line K-562  Biol Pharm Bull  2012  35(7):1132-6  PubMed ID: 22791162   DOI: 10.1248/bpb.b12-00159

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ